NSCLC exhibits notable molecular heterogeneity, with key driver gene mutations including epidermal growth factor receptor (EGFR), kirsten ratsarcoma viral oncogene homolog (KRAS) and anaplastic lymphoma kinase. This evidence concerns the gene KRAS and non-small cell lung carcinoma.